Becton, Dickinson and Company $BDX Shares Bought by Pallas Capital Advisors LLC

Key Points

• Pallas Capital Advisors LLC significantly increased its stake in Becton, Dickinson and Company by 197.2% during the second quarter, now holding 6,607 shares valued at approximately $1,138,000.
• Several other institutional investors have also raised their positions in Becton, Dickinson, including Financiere des Professionnels with an 11.4% increase, reflecting a growing interest in the medical instruments supplier.
• Becton, Dickinson recently reported strong earnings, with an EPS of $3.68, exceeding estimates, and declared a quarterly dividend of $1.04 per share, translating to an annualized yield of 2.2%.

Pallas Capital Advisors LLC raised its stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 197.2% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 6,607 shares of the medical instruments supplier's stock after buying an additional 4,384 shares during the period. Pallas Capital Advisors LLC's holdings in Becton, Dickinson and Company were worth $1,138,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in BDX. Saudi Central Bank purchased a new position in Becton, Dickinson and Company during the first quarter valued at $26,000. Smallwood Wealth Investment Management LLC purchased a new stake in shares of Becton, Dickinson and Company in the first quarter valued at approximately $27,000. REAP Financial Group LLC grew its holdings in Becton, Dickinson and Company by 75.3% in the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after buying an additional 55 shares in the last quarter. Alpine Bank Wealth Management acquired a new stake in Becton, Dickinson and Company during the first quarter worth about $29,000. Finally, Cornerstone Planning Group LLC increased its holdings in shares of Becton, Dickinson and Company by 341.4% during the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after buying an additional 99 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on BDX shares. Barclays reduced their price target on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a research note on Tuesday, June 3rd. Wells Fargo & Company boosted their price objective on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a research report on Friday, August 8th. Piper Sandler reissued a "neutral" rating and issued a $200.00 target price (up previously from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Morgan Stanley boosted their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Finally, Wall Street Zen upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Four research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $213.30.

Becton, Dickinson and Company Price Performance

Shares of BDX stock traded down $0.30 during trading hours on Monday, hitting $186.74. The company's stock had a trading volume of 1,227,724 shares, compared to its average volume of 1,592,393. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99. The stock has a market cap of $53.53 billion, a price-to-earnings ratio of 33.59, a P/E/G ratio of 1.51 and a beta of 0.27. The business has a fifty day moving average of $187.84 and a 200-day moving average of $189.61. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, topping analysts' consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. During the same quarter in the prior year, the company posted $3.50 EPS. The business's revenue for the quarter was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be issued a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio is currently 74.82%.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction on Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the sale, the executive vice president directly owned 4,887 shares of the company's stock, valued at approximately $881,077.23. This represents a 19.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Claire Fraser sold 917 shares of the firm's stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares in the company, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 2,965 shares of company stock valued at $551,536. Company insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.